Inactive Instrument
DUCAT VENTURES Share Price London S.E.
Stocks
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 09-08 | OptiBiotix Health plc Provides Update on SweetBiotix Product Range | CI |
| 09-02 | Corero wins deal; Talisman kicks off Tirzzit drilling | AN |
| Market Cap | 6.15M 8.33M 7.16M 6.75M 11.5M 792M 11.55M 79.95M 30.9M 404M 31.26M 30.58M 1.28B | P/E 2024 |
-9.76x | P/E 2025 | -1.76x |
|---|---|---|---|---|---|
| Enterprise Value | 5.11M 6.92M 5.96M 5.61M 9.56M 659M 9.6M 66.46M 25.69M 336M 25.99M 25.42M 1.06B | EV / Sales 2024 |
19.4x | EV / Sales 2025 | 5.09x |
| Free-Float |
88.62% | Yield 2024 * |
-
| Yield 2025 | - |
| 16/09/25 | OptiBiotix Health : Financial document (interims 2025) | PU |
| 30/06/25 | OptiBiotix Health : Annual Report (ar2024) | PU |
| 30/06/25 | OptiBiotix Health : Financial document (prelims 2024) | PU |
| 27/09/24 | OptiBiotix Health : Results Report | PU |
| 28/06/24 | OptiBiotix Health : Results Report | PU |
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen O'Hara
CEO | Chief Executive Officer | 66 | 04/08/2014 |
David Blain
DFI | Director of Finance/CFO | 65 | 31/10/2024 |
Sofia Kolyda
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Sofia Kolyda
BRD | Director/Board Member | 53 | 03/07/2018 |
Stephen O'Hara
BRD | Director/Board Member | 66 | 04/08/2014 |
Richard Davidson
CHM | Chairman | 75 | 31/12/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.94% | +0.31% | +40.04% | +103.25% | 69.19B | ||
| -0.07% | -3.93% | +32.54% | +75.96% | 62.97B | ||
| +3.13% | +1.82% | -12.41% | +386.53% | 27.27B | ||
| -0.54% | -5.46% | -3.87% | -16.80% | 24.78B | ||
| -0.93% | -1.29% | +25.30% | +16.70% | 25.8B | ||
| -1.43% | -1.89% | +21.32% | -17.67% | 20.11B | ||
| -4.27% | +2.67% | +219.02% | +362.48% | 18.47B | ||
| -1.43% | -1.80% | -8.64% | +537.09% | 14.88B | ||
| +1.14% | -0.38% | +52.32% | +165.17% | 14.29B | ||
| Average | -0.57% | -0.31% | +40.62% | +179.19% | 30.86B | |
| Weighted average by Cap. | -0.46% | -0.76% | +36.47% | +141.03% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 870K 1.18M 1.01M 955K 1.63M 112M 1.63M 11.32M 4.37M 57.13M 4.43M 4.33M 181M | 1.17M 1.58M 1.36M 1.28M 2.18M 150M 2.19M 15.17M 5.86M 76.56M 5.93M 5.8M 243M |
| Net income | -1.8M -2.44M -2.1M -1.98M -3.38M -233M -3.39M -23.48M -9.07M -119M -9.18M -8.98M -375M | -3.89M -5.27M -4.53M -4.27M -7.28M -501M -7.31M -50.6M -19.56M -255M -19.79M -19.36M -809M |
| Net Debt | -739K -1M -861K -811K -1.38M -95.25M -1.39M -9.61M -3.72M -48.53M -3.76M -3.68M -154M | -1.04M -1.4M -1.21M -1.14M -1.94M -134M -1.95M -13.49M -5.21M -68.09M -5.27M -5.16M -216M |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
















